Computer Weekly

Secure Code Warrior CEO on surviving the AI ‘vulnerability apocalypse’

As enterprises embrace agentic AI and vibe coding, Secure Code Warrior CEO and co-founder Pieter Danhieux warns that ...
Rutland Herald

Azul Addresses the Java Runtime Security Blind Spot Autonomous AI Can Now Exploit

Azul, the trusted leader in enterprise Java for today’s AI and cloud-first world, today launched a free JVM vulnerability ...
Tech Times

Minecraft Chaos Cubed Is Live: Sulfur Caves, Vulkan Renderer, Hardcore Fix

Minecraft Chaos Cubed update is live today as Java Edition 26.2 and Bedrock Edition 26.30. The release adds Sulfur Caves, a block-absorbing mob with eight physics archetypes, a native Java friends ...

Thermochemical mantle plume identified as the likely origin of Earth's largest oceanic plateau

The Ontong Java Plateau in the western Pacific Ocean is the largest oceanic plateau on Earth, and its formation mechanism has not been well understood.
techtimes

Minecraft 26.2 Chaos Cubed Drops Tomorrow: Hardcore Exploit Closed, Vulkan Renderer Ships

Minecraft Java Edition 26.2 — officially named Chaos Cubed — is scheduled to launch on June 16, 2026, bringing with it a new underground biome, a mob with a physics-simulation twist, an experimental ...
IEEE

Comment Generator for Java using Deep Learning

Abstract: Working on a project is simple until we are the only ones involved and know all of the modules and processes. However, the issue occurs when a fresh developer works on your project after a ...
Forbes

Generate Biomedicines IPO Turns Heads

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...
Reuters

Generate Biomedicines shares fall in weak Nasdaq debut for drug developer

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...
MedCity News

Generate Biomedicines’ IPO Brings In $400M for Pivotal Tests of Severe Asthma Drug

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...
FierceBiotech

Behind Generate's 'feverish' race to raise $400M IPO while window remains open

Generate:Biomedicines has earmarked $300 million of its IPO funds to complete a pair of phase 3 asthma trials for its anti-TSLP antibody GB-0895. (Fabrice Cabaud/Stock/Getty Images Plus) ...
Bloomberg L.P.

Flagship-Backed Generate Biomedicines Raises $400 Million in IPO

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...
Reuters

Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO

Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of up to $2.17 billion in its U.S. initial public offering, tapping into a resurgent biotech market ...